SecBot SecBot
SECBOTREPLAY Home › Report › LGND

LGND · Ligand Pharmaceuticals reported strong fourth quarter and full year…

LIGAND PHARMACEUTICALS INC · 8-K filed Feb 26, 2026 at 07:05 ET

At the news

BULLISHIMPACT 8/10

8-K filed Feb 26, 2026 at 07:05 ET

Ligand Pharmaceuticals reported strong fourth quarter and full year 2025 financial results, driven by a 48% increase in royalty revenue. The company achieved GAAP net income of $124.5 million and core adjusted EPS of $8.13, exceeding prior guidance. Ligand is reaffirming its 2026 guidance of $245-$285 million in revenue and $8.00-$9.00 in adjusted EPS.

  • Full year 2025 revenue was $268.1 million, up from $167.1 million in 2024, driven by 48% growth in royalty revenue to $161.0 million
  • Core adjusted EPS was $8.13 for 2025, exceeding initial guidance by approximately 30%
  • GAAP net income was $124.5 million, a significant improvement from a $4.0 million net loss in 2024
  • Company reaffirmed 2026 guidance of $245-$285 million in revenue and $8.00-$9.00 in adjusted EPS

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access